Daewoong-AZ Korea start to jointly sell hyperlipidemia treatment ‘Crestor’
On the 11th, Daewoong Pharmaceutical(CEO Jong-ok Lee) announced it made a strategic joint sales agreement of ‘Crestor(generic name: rosuvastatin),’ a hyperlipidemia treatment, with AstraZeneca(CEO Liz Chatwin), and started to sell it from the 1st.
Under the joint sales agreement, Daewoong Pharm ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
